Stay in the Loop with the Newest Depo-Provera Lawsuit Updates
Update — 26 September 2026: A settlement has since been announced. On 15 June 2026, Pfizer and MDL leadership announced an agreement in principle to resolve eligible claims in Depo-Provera MDL 3140, before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida.
No financial terms have been disclosed — no aggregate, per-plaintiff or per-tier figure has been released. The parties signed a Master Settlement Agreement on 21 July 2026; Case Management Order No. 12 describes it as a private agreement governed by a confidentiality agreement, with settlement registration expected to be completed in November 2026 and payments beginning by the first quarter of 2027. The first bellwether trial (Toney v. Pfizer) was vacated after the agreement, which covers the MDL and related New York state-court cases (Case Management Order No. 12). See our Depo-Provera settlement amounts guide for current status.
The Depo-Provera Lawsuit Updates You Need Right Now
Table of Contents
- The Depo-Provera Lawsuit Updates You Need Right Now
- Understanding the Depo-Provera Lawsuit Update and Meningioma Risks
- Current Status of the Depo-Provera Multidistrict Litigation (MDL 3140)
- Eligibility and Evidence for a Depo-Provera Claim
- What the 2026 Settlement Means for Compensation
- Frequently Asked Questions about Depo-Provera Brain Tumors
- Conclusion
The Depo-Provera lawsuit updates most people are searching for comes down to this:
Quick Summary (as of October 2026):
Find out if you may have a claim
Answer a few questions and a trained case advisor will review your situation — most people finish in about a minute.
- Free — no cost, no obligation
- About a minute to complete
- Reviewed by a trained case advisor
- Nothing you submit is published
Your details are sent over a secure connection and reviewed confidentially.
| What’s Happening | Key Details |
|---|---|
| Cases pending | 6,412 in the federal MDL as of October 1, 2026 |
| MDL location | Northern District of Florida, Judge M. Casey Rodgers |
| MDL number | MDL 3140 |
| Core allegation | Pfizer failed to warn U.S. users about brain tumor (meningioma) risk |
| FDA label update | Meningioma warning added in December 2025 |
| Settlement status | Global agreement June 15, 2026; Master Settlement Agreement signed July 21, 2026; amounts confidential |
| Who may qualify | Women diagnosed with a meningioma after using Depo-Provera; the settlement’s eligibility criteria are private |
| Next key date | Settlement registration expected to be completed in November 2026 |
Thousands of women who used the Depo-Provera birth control shot are now suing Pfizer. They say the company knew – or should have known – that the drug raises the risk of developing meningioma brain tumors, but never warned them.
A landmark 2024 study published in the BMJ found that women who used Depo-Provera for more than one year were 5.6 times more likely to develop a meningioma. Even so, the U.S. label did not add a meningioma warning until December 2025, more than a year after Health Canada announced in October 2024 that the Canadian Depo-Provera product monograph had been updated with that risk.
The litigation moved quickly. On June 15, 2026, Pfizer and plaintiffs’ lead counsel reached a global agreement to resolve eligible MDL claims, and the parties signed a confidential Master Settlement Agreement on July 21, 2026.
If you or someone you love used Depo-Provera and later received a brain tumor diagnosis, this guide will walk you through everything happening in the litigation right now.
I’m Mason Arnao, and my background in data systems and internet research has given me a unique lens for tracking complex litigation like the Depo-Provera lawsuit updates – cutting through the noise to surface what actually matters. In this guide, I’ll break down the latest court developments, who qualifies to file, and what potential compensation may look like.
Related Depo-Provera guides:
Understanding the Depo-Provera Lawsuit Update and Meningioma Risks
At the heart of every Depo-Provera lawsuit update is a single, terrifying medical term: intracranial meningioma. While these are the most common type of primary brain tumor-accounting for roughly 40% of all central nervous system neoplasms-learning you have a mass growing in your skull is life-altering.
What the Science Says
The link between Depo-Provera (medroxyprogesterone acetate or MPA) and brain tumors isn’t just a legal theory; it is rooted in significant scientific research on progestogen and meningioma risk.
- The 2024 BMJ Study: This massive French study analyzed over 18,000 women who underwent surgery for meningiomas. It revealed that using injectable MPA for more than a year resulted in a 5.6-fold increased risk of developing these tumors.
- The 2025 Cleveland Clinic Study: Published in JAMA Neurology, this study looked at data from more than 10 million patients. It found a relative risk of 2.43 for a meningioma diagnosis with depot medroxyprogesterone acetate compared with controls, or about one additional meningioma for every 1,152 patients treated, with the increased risk confined to more than four years of use or starting after age 31.
- The 2025 UBC Study: Researchers at the University of British Columbia reported a 3.55-fold higher meningioma rate with more than one year of medroxyprogesterone acetate use compared with users of an ethinylestradiol–levonorgestrel pill. The results were first posted as a preprint in February 2025, before peer review.
Why Depo-Provera?
Meningiomas are hormone-sensitive. They often feature high concentrations of progesterone receptors. Because Depo-Provera is a high-dose progestogen-delivered as a 150mg injection every three months-it essentially “feeds” these receptors. Scientists have suspected this link since at least 1983, yet Pfizer is accused of keeping this information off U.S. labels while updating them in other countries.
If you are concerned about your health history, you can read more about the Depo Shot Brain Tumor connection and ask yourself: Does Depo Provera Cause Brain Tumors? The mounting evidence suggests the answer is a resounding yes for many long-term users. For a deeper dive into the data, see this scientific study on MPA and meningioma safety.
Current Status of the Depo-Provera Multidistrict Litigation (MDL 3140)
If you’re looking for a Depo-Provera lawsuit update regarding the “where” and “who,” the answer is the Northern District of Florida. In February 2025, the Judicial Panel on Multidistrict Litigation (JPML) consolidated federal cases into MDL 3140.
The Courtroom Players
The litigation is presided over by Judge M. Casey Rodgers. If that name sounds familiar, it’s because she oversaw the massive 3M earplug litigation, one of the largest mass torts in history. Her experience is vital because this MDL is growing at a breakneck pace.
Discovery and Pfizer’s Defense
Before the settlement, the case went through “discovery,” the phase when both sides exchange evidence.
Pfizer’s primary legal shield was the “preemption” defense: it argued that because the FDA regulates drug labels, it could not have added a warning without federal permission. Plaintiffs argued that Pfizer withheld the very data the FDA would have needed to require a warning sooner. On June 15, 2026, after the global agreement, Judge Rodgers postponed ruling on Pfizer’s preemption motion.
For those tracking the timeline, check out our Depo-Provera lawsuit updates and the Depo-Provera Class Action Lawsuit 2024 summary to see how we got here.
Latest Depo-Provera Lawsuit Updates: Case Counts and Filings
As of October 1, 2026, 6,412 actions were pending in MDL 3140, according to the Judicial Panel on Multidistrict Litigation. This reflects a massive influx of women who only recently discovered the link between their past birth control use and their current neurological struggles. These are filed as individual damage claims within the Depo Provera Lawsuits, meaning each woman’s specific medical history and suffering will be evaluated on its own merits.
How to Join the Litigation Following a Depo-Provera Lawsuit Update
Think you might have a claim? You aren’t too late, but you need to act. The discovery rule is your best friend here. Even if you were diagnosed years ago, the “clock” for the statute of limitations typically doesn’t start until you knew (or should have known) that Depo-Provera caused your injury. Since the major studies only came out in 2024 and 2025, many women may still be within their state’s filing deadline, although that depends on state law and each person’s facts.
To start, you’ll need to confirm you meet the Depo-Provera Lawsuit Qualifications. If you do, your attorney will help you fill out the Plaintiff Proof of Use/Injury Questionnaire through the BrownGreer MDL Centrality portal. This is a mandatory step to stay active in the MDL. Check your status with our Depo-Provera Lawsuit Eligibility 2025 guide.
Eligibility and Evidence for a Depo-Provera Claim
To be part of the next Depo-Provera lawsuit updates success story, you need more than just a hunch. You need a “paper trail.”
The Minimum Requirements
While every law firm has slightly different intake rules, the general consensus for the strongest cases includes:
- Usage: Records showing injections of brand-name Depo-Provera or an authorized generic (like those from Greenstone or Prasco).
- Duration: The 2024 BMJ study found the increased risk with use for more than one year.
- Diagnosis: A confirmed diagnosis of a cerebral or spinal meningioma.
Essential Evidence
You will need to gather:
- Pharmacy Records: Proving you received the shots.
- Medical Records: Specifically the “op reports” if you had surgery.
- Imaging: MRI or CT scans showing the location and size of the tumor.
- Pathology Reports: To confirm the tumor type (Grade I, II, or III).
For a complete list of what you need, refer to our Depo-Provera Lawsuit Criteria Guide and the Depo-Provera Injury Claim Complete Guide. Understanding the Depo-Provera Severe Side Effects Guide can also help you identify symptoms you might have overlooked in the past.
What the 2026 Settlement Means for Compensation
We know what everyone wants to know: “How much is my case worth?” The honest answer in 2026 is that no one outside the settlement knows. Pfizer and plaintiffs’ lead counsel reached a global agreement on June 15, 2026, and signed a Master Settlement Agreement on July 21, 2026. Case Management Order No. 12 describes it as a private agreement governed by a confidentiality agreement, so no aggregate, per-plaintiff or per-tier figure has been released. Any Depo-Provera payout tier you see online is an estimate, not a reported settlement amount.
The same order says settlement registration should be completed in November 2026, with the claims process and payments beginning to roll out by the first quarter of 2027. Because the MDL is not a class action, the court does not hold a fairness hearing on the settlement.
What Damages Can You Claim?
Compensation isn’t just about the tumor itself; it’s about how your life changed. You can seek money for:
- Medical Expenses: Surgery, radiation, imaging and follow-up care.
- Lost Wages: Time missed from work during recovery.
- Pain and Suffering: The emotional toll of a brain tumor diagnosis.
- Loss of Quality of Life: If you can no longer drive, work, or care for your family.
Check out the Depo-Provera Settlement Amounts Lawsuit Guide for more details, or try our Depo Provera Settlement Calculator for a personalized estimate. Our Depo-Provera Lawsuit Compensation Guide 2025 provides more background.
Still unsure where you stand?
Have a trained case advisor review your own facts — free, confidential, and with no obligation.
- Free — no cost, no obligation
- About a minute to complete
- Reviewed by a trained case advisor
- Nothing you submit is published
Your details are sent over a secure connection and reviewed confidentially.
Frequently Asked Questions about Depo-Provera Brain Tumors
What are the symptoms of a Depo-Provera brain tumor?
Meningiomas grow slowly, so symptoms often creep up on you. You should watch for:
- Persistent, worsening headaches.
- Changes in vision (blurriness, double vision, or loss of peripheral vision).
- Hearing loss or ringing in the ears.
- Seizures.
- Loss of smell.
- Weakness in arms or legs.
If you have a history of Depo-Provera use and experience these, consult a neurologist immediately. You can read a full list of Depo Provera Brain Tumor Symptoms here. These are considered Depo-Provera severe side effects.
Has the FDA issued a recall for Depo-Provera?
No, as of September 2026, Depo-Provera has not been recalled. However, the litigation has forced a major change. In December 2025, the FDA finally approved a new warning label that includes the risk of meningiomas. This follows years of “black box” warnings for bone density loss, which you can read about in our Depo-Provera Lawsuit Side Effects Guide. This label change is a huge win for the Birth Control Shot Lawsuit movement, as it essentially acknowledges the risk exists.
What is the statute of limitations for filing a claim?
This is the most common question in any Depo-Provera lawsuit update. The deadline varies by state (usually 2 to 3 years), but the discovery rule generally protects you. Because the scientific link wasn’t widely publicized until 2024, many courts will rule that your “timer” didn’t start until then.
However, if a court finds fraudulent concealment (hiding the risk), those deadlines could be extended even further through “equitable tolling.” Don’t guess on this-consult our Depo-Provera Lawsuit Payout Date Guide and the Depo-Provera Lawsuit News Ultimate Guide for help.
Conclusion
The Depo-Provera lawsuit update landscape is shifting every single week. With 6,412 cases pending as of October 1, 2026 and a confidential Master Settlement Agreement signed in July 2026, the focus has shifted to who qualifies and how settlement registration works.
At Tort Advisor, we believe no woman should have to choose between effective birth control and her long-term neurological health. We connect clients with top-rated specialty attorneys who have proven results in complex pharmaceutical litigation. Whether you are in Alabama, California, Florida, or any of our 50+ service locations, we can help ensure you aren’t fighting this battle alone.
If you’re ready to take the next step, read our Depo Provera Lawsuit Complete Guide or contact us for a free case review today. Your health and your rights are worth the fight.
Additional Resources
Related Posts
The Supreme Court's June 25, 2026 ruling in Monsanto v. Durnell held that FIFRA can preempt state failure-to-warn claims, unsettling a central theory in paraquat cases. With 6,666 actions pending in MDL 3004 and a global settlement agreed in principle but no terms disclosed, here is what is verified and what is not.
Quick Answer: The Suboxone dental injury lawsuit update for August 2026 centers on MDL 3092, the federal litigation involving claims [...]
Quick Answer: The Depo-Provera lawsuit statute of limitations typically runs one to six years from the date of diagnosis, depending [...]
